A5053172275- Monoclonal and Polyclonal Antibodies Research
- Genetic factors in colorectal cancer
- Multiple and Secondary Primary Cancers
- BRCA gene mutations in cancer
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer survivorship and care
- Cancer Research and Treatments
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- PI3K/AKT/mTOR signaling in cancer
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Breast Cancer Treatment Studies
- Melanoma and MAPK Pathways
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Renal cell carcinoma treatment
- CAR-T cell therapy research
- Glycosylation and Glycoproteins Research
Sylvester Comprehensive Cancer Center
2007-2025
University of Miami
2007-2025
CT Group Of Institutions
2024
Memorial Healthcare System
2013-2022
University of Miami Health System
2020
University of Minnesota
2019
Memorial Hospital
2016
Cancer Institute (WIA)
2015
The TAPUR Study is a phase II basket trial that aims to identify signals of antitumor activity commercially available targeted agents in patients with advanced cancers harboring genomic alterations known be drug targets. Results cohort metastatic breast cancer (mBC) high tumor mutational burden (HTMB) treated pembrolizumab are reported.Patients mBC received standard doses either 2 mg/kg or 200 mg infusions every 3 weeks. Simon's two-stage design was used primary study end point disease...
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a phase II pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancer genomic alterations known to be drug targets. Results cohort non-small-cell lung (NSCLC) CDKN2A treated palbociclib are reported.Eligible were ≥ 18 years old NSCLC, no remaining standard treatment options, measurable disease, Eastern Cooperative Oncology Group performance status 0 2,...
In this multicenter, open-label, randomized phase II investigator-sponsored neoadjuvant trial with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials NCT00769470), participants early-stage HER2-positive breast cancer (N = 128) were recruited from 13 United States oncology centers throughout the Translational Research in Oncology network. Participants to receive trastuzumab (T; N 34), lapatinib (L; 36), or both (TL; 58) as HER2-targeted therapy, each participant...
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a pragmatic basket trial evaluating antitumor activity of approved targeted agents in patients with advanced cancers harboring potentially actionable genomic alterations. Data from cohorts high tumor mutational burden (HTMB, defined as ≥9 mutations per megabase) colorectal cancer (CRC) other treated pembrolizumab are reported.Eligible were 18 years older measurable tumors lack standard treatment options, an Eastern...
Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Prevention and Health Promotion. PCD provides an open exchange of information knowledge among researchers, practitioners, policy makers, others who strive to improve health public through chronic disease prevention.
The addition of trastuzumab to chemotherapy extends survival among patients with HER2(+) breast cancer. Prior work showed that and augments HER2 extracellular domain (ECD)-specific antibodies. current study investigated whether combination therapy induced immune responses beyond HER2-ECD and, importantly, those were associated survival. Pretreatment posttreatment sera obtained from 48 women metastatic cancer on NCCTG (now Alliance for Clinical Trials in Oncology) studies, N0337 N983252. IgG...
Describe the feasibility and implementation of an electronic health record (EHR)-integrated symptom needs screening referral system in a diverse racial/ethnic patient population ambulatory oncology.
Abstract The occurrence of multiple primary cancers (MPC) is thought to reflect increased cancer susceptibility in patients due a combination genetic and environmental factors. Here we conducted retrospective review 2,894 consecutive evaluated at single institution identified 31 (1.14%) individuals with history three or more cancers, then analyzed the influences associated their propensity for developing malignancies. We found that 35.5% had hereditary syndrome (HCS), high penetrance HCS...
1014 Background: TAPUR is a phase II basket study evaluating the anti-tumor activity of commercially available targeted agents in pts with advanced cancers specific genomic alterations. P an immune checkpoint inhibitor and HTMB emerging predictive biomarker for therapy. Results cohort MBC treated are reported. Methods: Eligible had cancer, no standard treatment options, ECOG PS 0-1, measurable disease acceptable organ function. Genomic testing was performed using tests selected by sites. Pts...
PURPOSE TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. The results cohort colorectal (CRC) BRAF mutations treated cobimetinib (C) plus vemurafenib (V) are reported. METHODS Eligible had CRC, no standard treatment options, measurable disease (RECIST), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, tumors...
Abstract Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers specific genomic alterations. Results cohort solid tumors ATM mutation (mut) or deletion (del) treated Tala are reported. Methods: Eligible had metastatic tumors, measurable disease, ECOG performance status (PS) 0-2, adequate organ function, and no standard treatment (tx) options. Genomic testing was performed CLIA-certified,...
Abstract Background: Bria-IMT™ is a combination immunotherapy consisting of allogeneic whole-cell cancer vaccine (SV-BR-1-GM) administered w/ immune checkpoint inhibitor (CPI). SV-BR-1-GM breast cells have been engineered to directly stimulate anti-tumor immunity through expression tumor-associated antigens and secretion GM-CSF enhance dendritic cell activation. Addition CPI potentiates overcome the immune-suppressive tumor microenvironment. Methods: This Phase I randomized phase II study...
3008 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers genomic alterations. Results cohort solid tumors BRAF V600E/D/K/R mutation (mut) treated C+V are reported. Methods: Eligible had tumors, no standard treatment (tx) options, measurable disease, ECOG performance status (PS) 0-2, and adequate organ function. Genomic testing was performed CLIA-certified, CAP-accredited site selected labs. Pts...
PURPOSE The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer genomic alterations known to be drug targets. Results from cohorts metastatic breast (BC) FGFR1 FGFR2 treated sunitinib are reported. METHODS Eligible had measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, no standard treatment options....
Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer genomic alterations known to be drug targets. Results cohort soft tissue sarcoma cyclin-dependent kinase 4 (
The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers genomic alterations known to be drug targets. results cohort solid tumors BRAF mutations treated cobimetinib plus vemurafenib are reported.Eligible had measurable disease (RECIST v.1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, no standard treatment options....
This Phase I/IIa open-label, single-arm clinical trial addressing advanced, refractory, metastatic breast cancer was conducted at six medical centers in the United States. We repeated inoculations with irradiated SV-BR-1-GM, a cell line antigen-presenting activity engineered to release granulocyte-macrophage colony-stimulating factor (GM-CSF), pre-dose low-dose cyclophosphamide and post-dose local interferon alpha. Twenty-six patients were enrolled; 23 (88.5%) inoculated, receiving total of...
Resected HER2 breast cancer patients treated with adjuvant trastuzumab and chemotherapy have superior survival compared to alone. We previously showed that induce HER2-specific antibodies which correlate improved in metastatic patients. It remains unclear whether the generation of immunity required endogenous antibody is associated disease-free setting. In this study, we addressed question by analyzing serum anti-HER2 from a subset enrolled NCCTG trial N9831, includes an arm (Arm A) was not...
Abstract Objectives This paper presents the results of a study developed to inform design multigenerational digital lifestyle intervention for overweight/obese women cancer survivors and their families. We followed first six phases Integrate, Design, Assess, Share (IDEAS) framework. Methods Grandmothers with breast, endometrial, or ovarian cancers (n = 46; 66.1 ± 0.9 years old; 34% Hispanic, 33% non‐Hispanic black, white) self‐reported behaviors, family structure, mobile device use, interest...
4637 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers genomic alterations. Results cohort pancreatic cancer germline or somatic BRCA1/2 inactivating mutations treated O are reported. Methods: Eligible had cancer, no standard treatment (tx) options available, measurable disease, ECOG Performance Status (PS) 0-2, and adequate organ function. Genomic testing was performed CLIA-certified,...
PURPOSE Targeted Agent and Profiling Utilization Registry (TAPUR) is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer genomic alterations known to be drug targets. Results cohort pancreatic BRCA1/ 2 mutations treated olaparib are reported. METHODS Eligible had cancer, measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, no standard treatment options...
1022 Background: The Bria-IMT regimen is a combination immunotherapy using an allogeneic whole cell cancer vaccine combined with checkpoint inhibitors (CPIs). Intradermally administered irradiated SV-BR-1-GM breast cells secrete GM-CSF and present tumor associated antigens (TAAs) on HLA-I –II molecules to directly stimulate anti-tumor immunity. Anti-PD1 CPI further stimulates T-cells synergizes SV-BR-1-GM. Here we report the results of phase 1/2 trial (NCT03328026) in metastatic/advanced...
9041 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers genomic alterations. Results cohort NSCLC CDKN2A loss or mutation treated P are reported. Methods: Eligible had NSCLC, no standard treatment options, measurable disease, ECOG PS 0-2 and adequate organ function. Genomic testing was performed using tests. Pts matched to RB mutations. A Simon two-stage design used test null rate 15% vs. 35%...